The role of ocular blood flow in OAG

Article

Ocular blood flow alterations and previous visual field damage may play an important role in visual field progression in open angle glaucoma (OAG), according to Antonio Martinez and colleagues from the Instituto Gallego de Oftalmologia, Spain.

Ocular blood flow alterations and previous visual field damage may play an important role in visual field progression in open angle glaucoma (OAG), according to Antonio Martinez and colleagues from the Instituto Gallego de Oftalmologia, Spain.

All OAG patients recruited or referred to one centre between January and July 2001 were examined. Kaplan-Meier survival analysis was used to estimate visual field progression and variables considered to be possible risk factors were evaluated using the one-way analysis of variance (ANOVA) and Cox proportional hazards regression analysis.

A total of 40 patients were evaluated during the trial period. Mean time to progression was 37.88 months, 95% confidence interval 33.10-42.65. Sixteen patients (40%) showed visual field progression. Significant risk factors included pattern standard deviation, end-diastolic velocity in the ophthalmic artery and resistance index in the ophthalmic artery.

The results suggest that ocular blood flow alterations may play a central role in the visual field progression in OAG patients.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.